present
antivir
drug
formal
licens
clinic
use
treatment
viral
infect
tabl
mainli
use
treatment
infect
caus
human
immunodefici
viru
hiv
hepat
b
viru
hbv
herp
virus
herp
simplex
viru
hsv
varicellazost
viru
vzv
cytomegaloviru
cmv
orthomyxovirus
influenza
paramyxovirus
respiratori
syncyti
viru
rsv
hepacivirus
hepat
c
viru
hcv
virus
demand
antivir
therapi
prompt
search
new
antivir
strategi
drug
direct
toward
either
molecular
target
approv
antivir
drug
target
newli
describ
antivir
compound
current
develop
target
hiv
hbv
hcv
target
hsv
vzv
cmv
addit
mani
import
viral
pathogen
medic
intervent
either
prophylact
therapeut
urgent
need
among
dna
virus
papillomavirus
human
papilloma
viru
hpv
adenovirus
poxvirus
variola
vaccinia
monkeypox
tabl
past
present
futur
antivir
drug
etc
herpesvirus
epsteinbarr
ebv
human
herpesviru
type
hhv
among
rna
virus
enterovirus
eg
coxsacki
b
echo
coronavirus
eg
sever
acut
respiratori
syndrom
sar
associ
coronaviru
flavivirus
eg
dengu
yellow
fever
rna
virus
associ
hemorrhag
fever
arenavirus
eg
lassa
fever
bunyavirus
eg
rift
valley
fever
crimeancongo
fever
filovirus
eg
ebola
marburg
describ
viral
famili
antivir
drug
formal
approv
compound
clinic
develop
thu
may
consid
antivir
drug
candid
compound
preclin
stage
develop
still
long
rout
ahead
could
qualifi
antivir
drug
viru
famili
address
follow
parvo
polyoma
papilloma
adeno
herp
pox
hepadna
picorna
flavi
hepaci
corona
orthomyxo
paramyxo
arena
bunya
rhabdo
filo
reo
retrovirus
signific
attempt
made
develop
compound
potenti
activ
parvoviru
pathogen
human
respons
erythema
infectiosum
socal
fifth
diseas
children
antivir
drug
formal
approv
treatment
polyomaviru
jc
bk
associ
diseas
progress
multifoc
leukoencephalopathi
pml
hemorrhag
cystiti
patient
acquir
immun
defici
syndrom
aid
howev
anecdot
case
report
point
efficaci
cidofovir
cytosin
hpmpc
licens
trademark
name
vistid
intraven
treatment
cmv
retin
aid
patient
treatment
polyoma
jc
bk
viru
infect
particularli
pml
aid
patient
polyomavirus
antivir
licens
treatment
human
papillomavirusassoci
diseas
includ
wart
condylomata
acuminata
papilloma
cervic
vulvar
penil
peri
anal
dysplasia
evolv
carcinoma
cidofovir
use
label
success
topic
occasion
system
treatment
hpvassoci
papillomat
lesion
mani
instanc
virtual
complet
durabl
resolut
lesion
achiev
follow
topic
applic
cidofovir
gel
cream
addit
cidofovir
acycl
nucleosid
phosphon
cprpmedap
n
explor
potenti
treatment
hpvassoci
papilloma
dysplasia
compound
shown
specif
induc
apoptosi
hpvinfect
cell
turn
may
relat
abil
restor
function
tumor
suppressor
protein
prb
neutral
oncoprotein
respect
hpvinfect
cell
recent
biphenylsulfonacet
acid
deriv
describ
inhibitor
hpv
helicaseassoci
atp
hydrolysi
although
novel
atpas
inhibitor
hardli
consid
good
drug
candid
may
serv
lead
optim
potenti
antivir
agent
activ
multipl
hpv
type
treatment
adenoviru
infect
quit
sever
immunocompromis
patient
eg
allogen
hematopoiet
stemcel
transplant
recipi
antivir
drug
offici
approv
anecdot
report
point
efficaci
cidofovir
adenoviru
infect
patient
among
novel
compound
could
explor
treatment
adenoviru
infect
propoxi
pyrimidin
hpmpodapi
akin
older
compound
like
adenin
hpmpa
acycl
nucleosid
purin
dideoxynucleosid
zalcitabin
ddc
alovudin
fddt
flt
found
inhibit
adenoviru
replic
vitro
also
ether
lipidest
hexadecyloxypropyl
hdp
octadecyloxyethyl
ode
prodrug
hpmpc
treatment
vzv
number
compound
approv
acyclovir
oral
prodrug
valaciclovir
penciclovir
oral
prodrug
famciclovir
idoxuridin
trifluridin
brivudin
penciclovir
idoxuridin
trifluridin
use
topic
primarili
treatment
herp
labiali
penciclovir
herpet
kerat
idoxuridin
trifluridin
acyclovir
use
oral
intraven
topic
wherea
valaciclovir
famciclovir
administ
oral
treatment
hsv
vzv
infect
brivudin
avail
european
countri
use
oral
treatment
herp
zoster
also
effect
infect
acyclovir
oral
prodrug
valaciclovir
remain
gold
standard
treatment
hsv
vzv
infect
attempt
made
bring
antihsv
antivzv
agent
clinic
except
prodrug
quit
number
year
still
clinic
develop
treatment
herp
zoster
worth
consid
clinic
develop
antihsv
antivzv
agent
number
carbocycl
guanosin
analog
cyclohexenylguanin
methylen
cyclopropan
synguanol
compound
owe
select
antivir
activ
specif
phosphoryl
hsvor
vzvencod
thymidin
kinas
tk
upon
phosphoryl
triphosph
form
act
chain
termin
dna
polymer
reaction
rare
circumst
hsv
vzv
becom
resist
acycl
carbocycl
guanosin
analog
due
tk
defici
tk
pyrophosph
analog
foscarnet
could
use
treat
tk
hsv
tk
vzv
infect
immunocompromis
patient
recent
second
gener
methylen
cyclopropan
analog
deriv
synthes
compound
may
potenti
treatment
vzv
also
betaherp
cmv
gammaherp
ebv
infect
particular
cyclopropavir
report
effect
reduc
mortal
mice
infect
murin
cmv
new
antihsv
agent
target
viral
helicaseprimas
complex
thiazolylphenyl
deriv
bil
bay
recent
report
vivo
efficaci
anim
model
infect
compound
seem
function
diminish
affin
helicaseprimas
complex
hsv
dna
antivir
potenc
bay
claim
superior
compound
current
use
treat
hsv
infect
lead
pursu
clinic
viewpoint
new
class
antivzv
compound
bicycl
furo
pyrimidin
nucleosid
analog
bcna
repres
cf
cf
compound
exquisit
activ
vzv
inhibit
replic
vzv
virus
includ
hsv
subnanomolar
concentr
select
index
excess
given
extrem
high
potenc
select
bcna
warrant
develop
toward
clinic
use
eg
herp
zoster
five
compound
licens
treat
cmv
infect
ganciclovir
oral
prodrug
valganciclovir
foscarnet
cidofovir
fomivirsen
except
fomivirsen
antisens
oligonucleotid
target
cmv
immediateearli
mrna
licens
anticmv
drug
target
viral
dna
polymeras
ganciclovir
must
first
phosphoryl
cmvencod
protein
kinas
gene
product
also
princip
site
mutat
engend
resist
toward
compound
toxic
side
effect
ie
bonemarrow
suppress
ganciclovir
nephrotox
foscarnet
cidofovir
sever
benzimidazol
ribonucleosid
includ
maribavir
previous
also
known
accredit
specif
activ
human
cmv
maribavir
seem
target
protein
kinas
gene
product
shown
account
releas
cmv
nucleocapsid
nucleu
maribavir
may
assum
target
stage
viral
life
cycl
follow
viral
dna
matur
packag
preclin
pharmacokinet
toxicolog
studi
shown
maribavir
favor
safeti
profil
excel
oral
bioavail
phase
iii
doseescal
trial
hivinfect
men
asymptomat
cmv
shed
indic
maribavir
rapidli
absorb
follow
oral
dose
reduc
cmv
titer
semen
maribavir
primarili
activ
cmv
cmv
potent
select
vitro
activ
three
human
betaherpesvirus
cmv
compar
ganciclovir
foscarnet
cmv
higher
antivir
potenc
lower
cytotox
target
earli
stage
viral
replic
cycl
follow
viral
entri
preced
viral
dna
replic
regul
cellular
process
may
involv
protein
tyrosin
kinas
activ
vitro
antivir
action
profil
cmv
deserv
explor
vivo
potenti
treatment
cmv
infect
present
standard
antivir
treatment
infect
compar
studi
foscarnet
cidofovir
emerg
potent
compound
highest
antivir
select
latter
three
also
prove
potent
howev
indic
clinic
use
agent
remain
illdefin
gammaherpesvirus
ebv
although
number
aforement
approv
antiherpet
drug
acyclovir
ganciclovir
brivudin
cidofovir
proven
effect
vitro
replic
ebv
none
antivir
drug
formal
approv
treatment
diseas
associ
ebv
eg
mononucleosi
infectiosa
bcell
lymphoma
lymphoprolif
syndrom
burkitt
lymphoma
nasopharyng
carcinoma
eg
kaposi
sarcoma
primari
effus
lymphoma
multicentr
castleman
diseas
would
seem
appeal
examin
establish
antiherpet
drug
cidofovir
acycl
nucleosid
phosphon
hpmpa
prodrug
thereof
potenti
therapi
ebvand
malign
also
new
nucleosid
analog
northmethanocarbathymidin
nmct
previous
shown
block
replic
explor
potenti
prevent
treatment
malign
particular
nmct
specif
triphosphoryl
cell
undergo
lytic
replic
effici
block
dna
replic
cell
poxvirus
variola
vaccinia
monkeypox
molluscum
contagiosum
orf
etc
sever
nucleosid
analog
eg
idoxuridin
nucleotid
analog
eg
cidofovir
hpmpodapi
proven
effect
variou
anim
model
poxviru
infect
particular
cidofovir
shown
high
efficaci
even
administr
singl
system
intraperiton
intranas
aerosol
dose
protect
mice
lethal
respiratori
infect
either
vaccinia
cowpox
cidofovir
demonstr
high
effect
treatment
dissemin
progress
vaccinia
athymicnud
mice
human
cidofovir
use
success
topic
intraven
rout
treatment
orf
recalcitr
molluscum
contagiosum
immunocompromis
patient
given
vitro
activ
cidofovir
variola
smallpox
vivo
efficaci
cidofovir
variou
poxviru
infect
anim
model
human
reason
virus
viral
diseas
assum
cidofovir
effect
therapi
andor
prophylaxi
smallpox
case
inadvert
outbreak
biolog
attack
variola
viru
phosphon
analog
cidofovir
limit
oral
bioavail
case
outbreak
smallpox
would
use
oral
activ
drug
hand
end
hexadecyloxypropylcidofovir
hdpcdv
octadecyloxyethylcidofovir
odecdv
design
potenti
oral
prodrug
cidofovir
alkyloxyalkyl
ester
cidofovir
found
significantli
enhanc
inhibit
replic
orthopoxvirus
eg
vaccinia
cowpox
vitro
hdpcdv
odecdv
given
oral
effect
cidofovir
given
parenter
treatment
vaccinia
cowpox
infect
hdpcdv
also
proven
effect
treatment
lethal
vaccinia
viru
respiratori
infect
mice
furthermor
hdpcdv
odecdv
given
oral
prove
highli
efficaci
lethal
aerosol
mousepox
ectromelia
viru
model
attest
potenti
use
alkyloxyalkyl
ester
cidofovir
oral
therapi
prophylaxi
poxviru
infect
ch
ho
n
hn
n
n
nh
p
ch
ch
ch
oh
ho
nmct
northmethanocarbathymidin
fact
attest
recent
find
cidofovir
mice
infect
ectromelia
mousepox
viru
encod
monkey
infect
monkeypox
cidofovir
cdv
hdpcdv
andor
odecdv
still
provid
best
current
hope
effect
control
virul
poxviru
infect
addit
nucleotid
analog
cidofovir
primarili
act
viral
dna
chain
termin
vaccinia
viru
dna
polymeras
incorpor
penultim
posit
antivir
strategi
poxviru
infect
may
also
base
inhibitor
cellular
process
ie
signal
transduct
pathway
respect
erbb
tyrosin
kinas
inhibitor
found
block
variola
viru
replic
vitro
vaccinia
viru
infect
vivo
likewis
gleevec
imatimib
ablfamili
kinas
inhibitor
use
treat
chronic
myelogen
leukemia
human
shown
suppress
poxvir
dissemin
vivo
sever
order
magnitud
promot
surviv
infect
mice
suggest
possibl
use
drug
treat
smallpox
complic
associ
vaccin
smallpox
drug
target
host
rather
viral
molecul
less
like
engend
resist
compar
specif
antivir
agent
collect
inhibitor
hostsign
pathway
exploit
poxvir
pathogen
may
repres
potenti
antivir
therapi
recent
new
antipoxviru
compound
describ
oral
bioavail
act
accord
novel
mechan
action
target
specif
viral
product
ie
vaccinia
viru
requir
extracellular
viru
particl
format
protect
mice
lethal
orthopoxviru
challeng
properti
make
attract
candid
develop
smallpox
antivir
drug
could
stockpil
use
treatment
prevent
smallpox
viru
infect
event
bioterrorist
threat
estim
million
peopl
worldwid
chronic
infect
hepadnaviru
hbv
approxim
million
die
year
complic
infect
includ
cirrhosi
hepatocellular
carcinoma
endstag
liver
diseas
formal
approv
treatment
chronic
hepat
b
lamivudin
adefovir
dipivoxil
pegyl
entecavir
wherea
lamivudin
adefovir
entacavir
nucleosid
analog
still
pre
clinic
develop
act
genuin
antivir
agent
hbvassoci
revers
transcriptas
interferon
chronic
hepat
b
set
primarili
act
immunomodul
pegyl
effect
treatment
hepat
b
eantigen
hbeag
posit
chronic
hepat
b
addit
benefit
achiev
combin
lamivudin
wherea
interferon
therapi
also
unavoid
side
effect
influenzalik
symptom
recommend
treatment
last
longer
year
nucleo
ide
analog
principl
administ
quit
number
year
lamivudin
howev
prolong
treatment
compound
emerg
virolog
clinic
resist
accumul
rate
approxim
patient
per
year
resist
adefovir
dipivoxil
may
also
emerg
much
less
frequent
year
adefovir
dipivoxil
oral
prodrug
adefovir
pmea
adenin
intracellular
convers
diphosph
form
act
competit
inhibitor
altern
substrat
hbv
revers
transcriptas
incorpor
dna
act
chain
termin
therebi
prevent
dna
chain
elong
adefovir
dipivoxil
bi
pivaloyloxymethyl
ester
adenin
bi
pom
pmea
hepsera
patient
chronic
hbv
infect
either
posit
neg
hbeag
week
treatment
dose
adefovir
dipivoxil
low
mg
day
result
signific
improv
paramet
diseas
histolog
liver
abnorm
serum
hbv
dna
titer
serum
alanin
aminotransferas
level
patient
hbeagneg
chronic
hepat
b
benefit
achiev
week
adefovir
dipivoxil
lost
treatment
discontinu
maintain
treatment
continu
week
entecavir
one
recent
antivir
drug
launch
clinic
use
vitro
vivo
potenc
seem
greater
lamivudin
patient
chronic
hepat
b
infect
proven
efficaci
dose
low
mg
day
activ
triphosph
metabolit
entecavir
would
accumul
intracellularli
concentr
inhibitori
hbv
dna
polymeras
translat
clinic
efficaci
entecavir
treatment
hbv
infect
remain
follow
addit
entecavir
number
lnucleosid
eg
blthymidin
ldt
telbivudin
interest
recommend
propos
care
patient
chronic
hbv
hiv
coinfect
put
combin
tdf
ftc
would
cover
hbv
hiv
infect
antiretrovir
therapi
use
patient
adefovir
dipivoxil
andor
pegyl
interferon
could
instal
depend
whether
hbeagneg
posit
respect
picornavirus
enteroand
rhinovirus
among
enterovirus
polio
hepat
effici
control
vaccin
polio
live
attenu
inactiv
kill
viru
vaccin
avail
wherea
hepat
inactiv
viru
vaccin
avail
enterovirus
coxsacki
b
echovirus
rhinovirus
need
approach
chemotherapeut
agent
singl
antivir
drug
ever
licens
clinic
use
enteroor
rhinoviru
infect
extens
studi
potenti
enterovirus
pleconaril
compound
bind
hydrophob
pocket
beneath
canyon
floor
capsid
protein
picornavirus
therebi
freez
viral
capsid
prevent
dissoci
uncoat
viral
rna
genom
clinic
efficaci
pleconaril
evalu
experiment
induc
enteroviru
coxsacki
respiratori
infect
adult
volunt
compassion
basi
potenti
lifethreaten
enteroviru
infect
pleconaril
also
shown
reduc
durat
sever
picornavirusassoci
viral
respiratori
ill
adolesc
adult
virus
viral
diseas
prevent
andor
treatment
rhinoviru
infect
common
cold
inhibitor
human
rhinoviru
hrv
proteas
extens
investig
ruprintrivir
irrevers
proteas
inhibitor
upon
intranas
administr
human
volunt
appear
safe
well
toler
experiment
induc
rhinoviru
cold
healthi
volunt
ruprintrivir
prophylaxi
reduc
proport
subject
posit
viral
cultur
decreas
frequenc
cold
anoth
irrevers
inhibitor
hrv
proteas
refer
pyrrolidinyl
penteno
acid
ethyl
ester
compound
compound
offer
advantag
oral
bioavail
healthi
volunt
singl
oral
dose
compound
appear
safe
well
toler
although
compound
current
progress
toward
clinic
develop
great
need
antivir
treatment
often
sever
complic
coxsacki
b
viru
infect
myocard
may
lead
idiopath
dilat
cardiomyopathi
mice
coxsacki
virusinduc
myocard
inhibit
immunosuppress
agent
mycophenol
acid
mpa
mofetil
benefici
outcom
must
appar
result
immunosuppress
effect
mpa
inhibit
imp
dehydrogenas
henc
gtp
suppli
sinc
mpa
reduc
infecti
viru
titer
myocard
pronounc
inhibitori
effect
coxsacki
virusinduc
myocard
accompani
mark
reduct
viru
titer
heart
obtain
interferon
induc
poli
poli
c
poli
poli
c
u
also
known
ampligen
lesser
extent
pegyl
combin
inhibitor
viral
replic
ampligen
immunosuppress
mpa
mofetil
could
ideal
treatment
strategi
viral
myocard
whether
due
coxsacki
b
virus
implement
treatment
regimen
clinic
set
address
flavivirus
yellow
fever
dengu
west
nile
etc
antivir
current
avail
treatment
flaviviru
infect
although
live
viru
vaccin
routin
use
prophylaxi
yellow
fever
prospect
effect
therapi
flaviviru
infect
seem
encourag
antivir
compound
ribavirin
weak
activ
flavivirus
greater
hope
may
vest
interferon
interferon
induc
base
infect
hamster
murin
modoc
viru
experiment
flaviviru
enceph
model
develop
reminisc
japanes
enceph
viru
infect
human
relat
model
modoc
viru
scid
mice
whether
pegyl
interferon
induc
poli
poli
c
ampligen
shown
significantli
delay
virusinduc
morbid
paralysi
mortal
due
progress
enceph
ribavirin
provid
benefici
effect
model
whether
given
alon
combin
interferon
current
approv
therapi
chronic
hepat
c
consist
pegyl
mg
parenter
weekli
combin
ribavirin
oral
daili
treatment
regimen
associ
sustain
viral
respons
least
patient
infect
hcv
genotyp
patient
infect
anoth
genotyp
hcv
durat
treatment
week
longer
patient
infect
hcv
genotyp
may
reduc
week
patient
infect
anoth
genotyp
interferon
appear
target
phosphoprotein
encod
nonstructur
gene
hcv
genom
wherea
ribavirin
akin
mpa
primarili
act
inhibitor
imp
dehydrogenas
thu
reduc
biosynthesi
gtp
combin
pegyl
interferon
ribavirin
also
advoc
therapi
hcv
infect
patient
hiv
coinfect
howev
forgotten
patient
treat
hiv
infect
azidothymidin
zidovudin
zdv
latter
may
antagon
ribavirin
therefor
reassur
note
ribavirin
mg
day
administ
combin
pegyl
interferon
significantli
affect
intracellular
phosphoryl
plasma
pharmacokinet
zdv
pyrimidin
dideoxynucleosid
hivhcv
coinfect
patient
hooc
h
co
addit
pegyl
interferon
pegyl
interferon
interferon
alreadi
use
develop
eg
albuferona
interferon
fuse
human
serum
albumin
allow
dose
interv
week
compar
week
pegyl
interferon
consensu
interferon
ie
combin
ribavirin
shown
achiev
higher
sustain
respons
rate
naiiv
patient
chronic
hepat
c
compar
standard
interferona
ribavirin
combin
pegyl
interferon
ribavirin
may
advantag
replac
viramidin
amidin
analog
convert
mainli
hepatocyt
adenosin
deaminas
ribavirin
latter
reduc
uptak
therefor
lesser
toxic
red
blood
cell
compar
ribavirin
viramidin
would
give
less
anemia
compar
ribavirin
phase
iii
studi
viramidin
combin
pegyl
interferon
compar
ribavirin
combin
pegyl
interferon
eagerli
await
assess
one
choos
ribavirin
viramidin
take
account
durat
combin
interferon
plu
ribavirin
treatment
therewith
associ
side
effect
cost
partial
respons
observ
treatment
regimen
fierc
attempt
made
right
develop
select
antihcv
agent
target
specif
viral
protein
proteas
rna
helicas
rna
replicas
rnadepend
rna
polymeras
also
hcv
protein
form
ion
channel
block
longalkylchain
iminosugar
deriv
consid
potenti
target
antivir
therapi
proof
principl
compound
target
proteas
could
reduc
plasma
concentr
hcv
rna
alreadi
deliv
biln
administ
oral
longer
day
patient
infect
hcv
genotyp
biln
ciluprevir
abl
reduc
hcv
rna
level
log
patient
infect
hcv
genotyp
day
treatment
anoth
proteas
inhibitor
differ
vitro
resist
profil
biln
ie
major
biln
mutat
fulli
suscept
similarli
domin
resist
mutat
remain
sensit
biln
thu
biln
elicit
resist
hcv
proteas
differ
mechan
mg
everi
h
found
achiev
end
treatment
main
reduct
hcv
rna
log
patient
dose
viru
becam
undetect
day
dose
overal
preclin
profil
support
candidaci
novel
oral
therapi
hepat
c
hcv
proteas
inhibitor
may
announc
futur
behav
similarli
variou
acidbas
macrocycl
inhibitor
hcv
proteas
well
sch
mechanismbas
inhibitor
hcv
proteas
preclin
develop
fact
latter
found
act
synergist
ainterferon
suppress
hcv
replicon
synthesi
addit
proteas
rna
replicas
also
perceiv
attract
target
develop
hcv
inhibitor
highli
potent
select
antivir
agent
target
viral
rna
replicas
describ
inhibit
replic
bovin
viral
diarrhea
viru
bvdv
pestiviru
could
consid
surrog
viru
hcv
recent
describ
novel
seri
compound
prototyp
methyl
pyridin
bpip
act
nonnucleosid
rna
replicas
inhibitor
nnrri
effect
highli
potent
select
inhibit
replic
bvdv
bpip
class
compound
new
congen
deriv
act
equal
effici
hcv
replic
futur
treatment
strategi
hcv
infect
nnrri
may
like
combin
nucleosid
rna
replicas
inhibitor
nrri
analog
strategi
follow
treatment
hiv
infect
nrti
combin
nnrti
see
sole
nrri
alreadi
proceed
phase
iii
clinic
trial
therapi
hepat
c
ovalin
ester
cmethylcytidin
valopicitabin
administ
oral
rout
show
enhanc
antivir
efficaci
combin
pegyl
interferon
addit
cmethylcytidin
sever
ribonucleosid
analog
nrri
report
inhibit
hcv
replic
omethylcytidin
cmethyladenosin
cmethyladenosin
cmethylguanosin
compound
act
nonoblig
chaintermin
nucleosid
analog
would
seem
interest
prepar
evalu
correspond
deoxyribonucleosid
analog
antihcv
activ
new
class
hcv
rna
replicas
inhibitor
repres
alpha
gammadiketo
acid
dka
one
activ
dka
dka
compound
compound
reminisc
dka
type
hiv
integras
inhibitor
see
assum
inhibit
hcv
polymer
activ
via
chelat
activ
site
mg
ion
certain
sens
may
consid
pyrophosph
mimic
act
productlik
inhibitor
polymeras
reaction
alloster
bind
site
compound
alreadi
identifi
crystallograph
studi
correspond
narrow
cleft
protein
surfac
thumb
domain
nm
enzym
catalyt
center
curious
nnrri
activ
hcv
polymeras
contain
besid
larg
hydrophob
region
carboxyl
acid
group
similar
motif
allow
hydrogen
bond
main
chain
amid
nitrogen
atom
ie
demonstr
phenylalanin
deriv
mutat
confer
resist
hcv
rna
replicas
ie
proteas
ie
v
v
identifi
mutat
confer
high
level
resist
biln
respect
howev
mutant
remain
suscept
nrri
class
nnrri
well
interferon
addit
dualli
biln
resist
mutant
display
significantli
reduc
replic
abil
compar
wildtyp
find
support
rational
drug
combin
therapi
hcv
infect
recent
review
sever
approach
includ
ribozym
antisens
oligonucleotid
rna
interfer
rnai
base
small
interf
si
rna
could
envisag
target
hcv
genom
particular
sirna
aim
posttranscript
gene
silenc
may
consid
attract
approach
hcv
sever
protein
encod
sar
coronaviru
could
consid
target
chemotherapeut
intervent
ie
spike
protein
main
proteas
ntpasehelicas
rnadepend
rna
polymeras
rna
replicas
possibl
viral
cellular
proteinmedi
process
sever
acut
respiratori
syndrom
sar
coronaviru
protein
mediat
infect
permiss
cell
interact
receptor
angiotensinconvert
enzym
ace
monoclon
antibodi
domain
found
neutral
viru
block
associ
receptor
ace
also
fusion
sar
coronaviru
cell
could
consid
attract
target
extent
fusion
process
bear
resembl
fusogen
mechan
hiv
ie
regard
heptad
repeat
interact
sixhelix
bundl
format
might
feasibl
develop
sar
coronaviru
inhibitor
analog
hiv
fusion
inhibitor
enfuvirtid
follow
receptor
bind
induc
conform
chang
spike
glycoprotein
third
step
would
involv
viral
entri
process
name
cathepsin
l
proteolysi
within
endosom
cathepsinlspecif
inhibitor
mdl
also
known
calpain
inhibitor
iii
zvalph
cho
time
inhibit
cathepsin
l
activ
proteinmedi
infect
ic
nm
mm
respect
addit
calpain
inhibitor
iii
calpain
inhibitor
describ
inhibitor
sar
coronaviru
replic
select
select
index
calpain
inhibitor
vi
cho
crystal
structur
sar
coronaviru
proteas
reveal
offer
solid
basi
ration
drug
design
sar
proteas
inhibitor
potenti
target
ntpasehelicas
rna
replicas
rnadepend
rna
polymeras
structur
basi
still
delin
number
peptidomimet
compound
aziridinyl
peptid
ketoglutamin
analog
chymotrypsinlik
proteas
inhibitor
peptid
anilid
report
inhibitor
sar
coronaviru
main
proteas
niclosamid
anilid
k
mm
ic
mm
prove
potent
competit
inhibitor
case
proteas
inhibitor
shown
inhibit
sar
coronaviru
proteas
activ
viru
replic
cell
cultur
exampl
pheph
dipeptid
inhibitor
found
inhibit
proteas
ic
mm
inhibit
viru
replic
vero
cell
ec
mm
toxic
host
cell
concentr
mm
select
index
octapeptid
specif
design
sar
coronaviru
main
proteas
name
avlqsgfr
report
inhibit
sar
coronaviru
replic
vero
cell
ec
mg
ml
cytotox
mg
ml
thu
establish
select
index
whether
highli
select
antivir
effect
actual
mediat
inhibit
sar
coronaviru
main
proteas
ascertain
studi
sar
coronaviru
ntpasehelicas
consid
potenti
target
develop
antisar
agent
bananin
three
deriv
iodobananin
vanillinbananin
eubananin
shown
inhibit
atpas
helicas
activ
sar
coronaviru
ntpasehelicas
ic
valu
atpas
activ
rang
mm
bananin
also
found
inhibit
sarscov
replic
fetal
rhesu
kidney
cell
ec
less
mm
cc
mm
thu
exhibit
select
index
wheter
antivir
effect
obtain
cell
cultur
causal
link
inhibit
ntpasehelicas
ascertain
sar
coronaviru
rnadepend
rna
polymeras
rdrp
pivot
role
viral
replic
repres
anoth
potenti
target
antisar
therapi
enzym
contain
hydrophob
pocket
nonnucleosid
inhibitor
similar
proven
effect
hcv
polymeras
revers
transcriptas
fact
nonnucleosid
revers
transcriptas
inhibitor
shown
evid
inhibitori
effect
sar
coronaviru
rdrp
activ
present
nucleosid
analog
recogn
specif
inhibitor
sar
coronaviru
rdrp
n
hydroxycytidin
accredit
antihcv
antisar
coronaviru
effect
sar
coronaviru
prove
activ
ec
mm
select
index
whether
antivir
effect
mediat
inhibit
viral
rdrp
ascertain
howev
wide
varieti
old
new
compound
report
inhibit
vitro
replic
sar
coronaviru
rel
high
concentr
mm
shortag
small
molecul
inhibit
replic
sar
viru
within
mm
higher
concentr
rang
whether
molecul
would
abl
prevent
suppress
sar
vivo
remain
determin
typic
exampl
miscellan
compound
often
illdefin
mode
action
select
index
sirna
develop
target
replicas
spike
gene
sar
coronaviru
genom
therebi
silenc
express
cell
cultur
potent
sirna
inhibitor
sar
coronaviru
vitro
ie
sirna
duplex
forward
sequenc
forward
sequenc
target
sar
coronaviru
genom
proteincod
nonstructur
region
respect
evalu
efficaci
rhesu
macaqu
sar
model
found
provid
relief
sar
coronaviru
infectioninduc
fever
diminish
sarscov
level
reduc
acut
diffus
alveolar
damag
whether
sar
conquer
sirna
approach
remain
proven
howev
shortli
sar
coronaviru
identifi
caus
agent
sar
interferon
shown
inhibit
replic
sar
coronaviru
cell
cultur
vitro
interferonb
potent
either
interferona
g
observ
subsequ
confirm
extend
sever
studi
interferonb
conjunct
interferong
found
synergist
inhibit
replic
sar
coronaviru
vero
cell
prophylact
rather
therapeut
agent
interferon
may
highest
util
prophylaxi
earli
postexposur
manag
sar
pegyl
interferona
shown
reduc
viral
replic
excret
viral
antigen
express
type
pneumocyt
attend
pulmonari
damag
cynomolg
macaqu
infect
experiment
sar
coronaviru
pegyl
interferona
commerci
avail
treatment
hepat
c
gener
use
combin
ribavirin
hepat
b
pegyl
interferona
well
commerci
avail
interferon
interferonb
etc
could
consid
prevent
andor
earli
postexposur
treatment
sar
reemerg
mani
year
amantadin
rimantadin
use
prophylaxi
therapi
influenza
viru
infect
never
gain
wide
accept
primarili
risk
rapid
emerg
drugresist
viru
mutant
compound
interact
specif
matrix
protein
function
hydrogen
ion
h
channel
help
decapsid
uncoat
influenza
viru
particl
influenza
virus
harbor
amantadin
resist
mutat
virul
wildtyp
viru
strain
recent
year
neuraminidas
inhibitor
zanamivir
oseltamivir
becom
avail
therapi
andor
prophylaxi
influenza
b
viru
infect
influenza
adopt
uniqu
replic
strategi
use
one
surfac
glycoprotein
hemagglutinin
h
bind
target
cell
receptor
contain
termin
sialic
acid
nacetylneuramin
acid
nana
anoth
surfac
glycoprotein
neuraminidas
n
cleav
termin
sialic
acid
thu
allow
viru
particl
leav
cell
viral
replic
cycl
complet
use
therapeut
neuraminidas
inhibitor
lead
reduct
ill
day
reduct
viru
transmiss
household
healthcar
contact
reduct
frequenc
sever
complic
sinus
bronchiti
diminish
use
antibiot
use
prophylact
neuraminidas
inhibitor
significantli
reduc
number
new
influenza
case
although
resist
human
influenza
virus
neuraminidas
inhibitor
develop
evid
natur
occur
resist
either
zanamivir
oseltamivir
zanamivir
oseltamivir
effect
influenza
b
among
influenza
prevail
variant
h
n
h
n
also
avian
flu
h
n
zanamivir
must
taken
oral
inhal
particular
oseltamivir
conveni
administ
oral
capsul
stockpil
confront
potenti
influenza
pandem
futur
increas
threat
avian
flu
need
suffici
suppli
neuraminidas
inhibitor
oseltamivir
zanamivir
becom
extrem
urgent
comparison
neuraminidas
inhibitor
exist
influenza
vaccin
like
limit
valu
newli
emerg
influenza
viru
strain
follow
zanamivir
oseltamivir
similar
structurebas
neuraminidas
inhibitor
develop
cyclopentan
deriv
peramivir
pyrrolidin
novel
neuraminidas
inhibitor
may
consid
potenti
drug
candid
amen
optim
lead
develop
yet
newer
compound
improv
activ
bioavail
andor
resist
profil
fact
peramivir
prove
effect
panel
five
zanamivirresist
six
oseltamivirresist
b
influenza
viru
strain
oseltamivir
resist
clinic
isol
human
influenza
associ
mutat
posit
neuraminidas
recent
resist
avian
influenza
h
n
oseltamivir
shown
caus
mutat
variant
still
appear
sensit
zanamivir
promin
among
neuraminidas
inhibitorresist
influenza
h
n
viru
mutat
yet
demonstr
h
n
v
wherea
mutat
associ
compromis
viru
growth
transmiss
growth
transmiss
v
variant
compar
wildtyp
viru
antivir
agent
besid
amantadin
rimantadin
neuraminidas
inhibitor
may
consid
potenti
prevent
andor
therapi
influenza
viru
infect
includ
avian
influenza
ribavirin
sinc
long
recogn
broadspectrum
antivir
agent
particular
activ
orthoand
paramyxovirus
recent
viramidin
carboxamidin
analog
ribavirin
shown
efficaci
similar
ribavirin
influenza
viru
infect
consid
lesser
toxic
viramidin
may
warrant
evalu
possibl
therapi
influenza
includ
h
n
yet
recent
describ
compound
specif
activ
influenza
b
c
virus
carboxamid
flutimid
would
target
viral
polymeras
capdepend
endonucleas
respect
paramyxovirus
parainfluenza
type
receiv
littl
attent
either
prevent
cur
viewpoint
mump
measl
like
rubelliviru
rubella
suffici
contain
vaccin
make
respiratori
syncyti
viru
rsv
human
metapneumoviru
hmpv
nipah
paramyxovirus
greatest
need
antivir
therapi
rsv
approv
antivir
therapi
aerosol
administr
ribavirin
practic
howev
ribavirin
rare
use
owe
technic
burden
deliveri
aerosol
given
circumst
rsv
bronchopneumon
young
infant
given
high
incid
rsv
infect
often
diagnos
influenza
high
yet
unmet
medic
need
appropri
therapi
prophylaxi
rsv
infect
hold
hmpv
infect
usual
occur
winter
season
rsv
mainli
young
children
elderli
peopl
immunocompromis
individu
ribavirin
certainli
hold
promis
treatment
hmpv
infect
recent
demonstr
mous
model
hmpv
also
mention
hcv
sirna
may
also
applic
properli
design
administ
intranas
treatment
respiratori
viru
infect
recent
number
small
molecul
eg
formerli
known
although
structur
dissimilar
shown
fit
small
hydrophob
caviti
inner
core
rsv
fusion
f
protein
therebi
interact
heptad
repeat
domain
inhibit
rsv
fusion
although
therapeut
potenti
compound
treatment
rsv
infect
present
unclear
doubt
explor
mechan
interact
inhibitor
f
protein
facilit
design
new
rsv
fusion
inhibitor
found
potent
inhibitor
rsv
replic
vitro
exhibit
excel
potenc
multipl
laboratori
clinic
isol
b
rsv
averag
ec
nm
inhibit
fusion
viral
cellular
lipid
membran
earli
viru
entri
stage
latestag
syncytium
format
shown
oral
activ
rsv
balbc
mice
cotton
rat
even
administ
singl
oral
dose
h
prior
intranas
rsv
inocul
could
consid
prototyp
lowmolecularweight
inhibitor
target
format
six
helic
coiledcoil
bundl
prelud
viruscel
fusion
rsv
also
hiv
although
human
parainfluenza
virus
import
respiratori
tract
pathogen
especi
children
receiv
littl
attent
either
prophylact
vaccin
therapeut
viewpoint
yet
contain
uniqu
target
major
surfac
glycoprotein
hemagglutininneuraminidas
hn
serv
time
cell
attach
viru
spread
hn
inhibitor
found
inhibit
function
block
infect
parainfluenza
virus
vitro
vivo
compound
may
limit
parainfluenza
viru
infect
human
compound
may
pursu
activ
parainfluenza
virus
rsv
well
influenza
virus
includ
flavonoid
uncinosid
ribavirin
proven
effect
postexposur
prophylaxi
therapi
experiment
arenaviru
infect
anim
model
anecdot
report
suggest
might
also
effect
treatment
arenaviru
infect
ie
machupo
sabia
human
convinc
evid
clinic
efficaci
obtain
case
lassa
fever
found
reduc
casefat
rate
irrespect
time
point
ill
treatment
start
bunyavirus
one
fear
highli
infecti
easili
transmit
human
associ
casefat
rate
approxim
crimeancongo
hemorrhag
fever
viru
bunyavirus
sensit
ribavirin
also
demonstr
experiment
anim
model
antivir
drug
current
clinic
use
includ
ribavirin
provid
meaning
protect
filovirus
vivo
possibl
therapeut
strategi
may
base
use
sadenosylhomocystein
sah
hydrolas
inhibitor
sah
hydrolas
inhibitor
interfer
sadenosylmethionin
sam
depend
methyl
reaction
particularli
involv
cap
viral
mrna
virus
rhabdoviru
vesicular
stomat
viru
vsv
reli
heavili
mrna
cap
particularli
sensit
inhibit
sah
hydrolas
inhibitor
includ
biochem
filoand
rhabdovirus
quit
similar
replic
machineri
requir
cap
mrna
sah
hydrolas
inhibitor
may
logic
expect
effect
treatment
ebola
viru
infect
fact
administ
singl
dose
mg
kg
found
protect
mice
lethal
infect
ebola
viru
zair
strain
protect
effect
accompani
probabl
mediat
product
high
concentr
interferon
ebola
virusinfect
mice
hypothes
block
cap
nascent
rna
viral
strand
henc
matur
toward
mrna
stimul
format
doublestrand
rna
complex
long
known
excel
induc
interferon
like
sah
hydrolas
inosin
monophosph
imp
dehydrogenas
anoth
cellular
enzym
may
envisag
target
antivir
agent
imp
dehydrogenas
crucial
enzym
involv
biosynthesi
gtp
although
ribavirin
may
act
distinct
virus
distinct
mechan
eg
imp
dehydrogenas
inhibit
immunomodulatori
effect
rna
cap
interfer
polymeras
inhibit
lethal
mutagenesi
predomin
mechan
ribavirin
exert
antivir
activ
vitro
flavivirus
paramyxovirus
mediat
inhibit
imp
dehydrogenas
recent
new
class
compound
phosphorodiamid
morpholino
oligom
pmo
conjug
argininerich
cellpenetr
peptid
ppmo
design
base
pair
translat
start
region
ebolaviru
positivesens
rna
report
inhibit
ebolaviru
replic
protect
mice
lethal
ebolaviru
infect
reovirus
rotaviru
associ
viral
gastrointestin
infect
far
clinic
import
pathogen
sever
attempt
still
made
develop
effect
vaccin
rotaviru
infect
current
treatment
rotaviru
diarrhea
mainli
base
administr
fluid
prevent
dehydr
attempt
develop
antivir
drug
diseas
although
worthi
note
replic
reo
rota
virus
exquisit
sensit
sah
hydrolas
inhibitor
present
compound
avail
treatment
hiv
infect
sever
compound
also
avail
fix
dose
combin
zidovudin
lamivudin
lamivudin
abacavir
emtricitabin
tenofovir
disoproxil
fumar
tripledrug
fix
dose
combin
contain
efavirenz
emtricitabin
tenofovir
disoproxil
fumar
forthcom
antagonist
stem
cell
mobil
stem
cell
transplant
patient
nonhodgkin
lymphoma
multipl
myeloma
antagonist
schc
vicriviroc
schd
sch
aplaviroc
maraviroc
nrti
racivir
dotc
accredit
activ
nrtiresist
strain
reverset
elvucitabin
alovudin
amdoxovir
nnrti
capravirin
etravirin
proteas
inhibitor
gag
matur
inhibitor
also
prodrug
benzophenon
cyclotriazadisulfonamid
cada
yet
compound
preclin
develop
andor
may
soon
proceed
clinic
phase
iii
clinic
trial
hiv
receptor
downmodul
cyclotriazadisulfonamid
cada
hiv
envelopebind
protein
cyanovirinn
topic
microbicid
antagonist
structur
relat
antagonist
deriv
bicyclam
current
pursu
phase
iiiii
clinic
trial
combin
granulocyt
colonystimul
factor
gcsf
mobil
autolog
hematopoiet
progenitor
cell
antagonist
structur
relat
prove
highli
potent
oral
bioavail
inhibitor
strain
act
synergist
antiretrovir
anoth
oral
bioavail
inhibitor
hiv
infect
prodrug
nrti
dideoxyguanosin
thymin
dioxolan
dot
anoth
nrti
deoxythymidin
favor
oral
bioavailab
uniqu
drug
resist
profil
differ
nrti
ntrti
phosphonomethoxi
alkoxi
pmpodapi
pmeodapi
deriv
thereof
deoxythreosyl
nucleosid
phoshon
phosphonomethyldeoxythreosyladenin
pmdta
thymin
pmdtt
nnrti
thiocarboxanilid
dapivirin
topic
microbicid
rilpivirin
one
potent
antihiv
agent
ever
describ
novel
benzophenon
nnrti
activ
nm
rt
mutant
associ
clinic
resist
efavirenz
nevirapin
respect
number
compound
includ
target
integras
repres
interest
platform
design
inhibitor
revers
transcriptas
rnase
h
well
hiv
integras
similarli
indolyl
aryl
sulfon
may
serv
platform
design
new
nnrti
effect
variant
recent
diketo
acid
bear
nucleobas
scaffold
describ
highli
potent
hiv
integras
inhibitor
prototyp
compound
acid
exhibit
antihiv
select
index
cell
cultur
addit
aforement
cyanovirinn
thiocarboxanilid
dapivirin
compound
could
develop
topic
eg
vagin
microbicid
name
aglycon
glycopeptid
antibiot
vancomycin
teicoplanin
eremomycin
specif
interact
glycoprotein
also
plant
lectin
eg
galanthu
nivali
agglutinin
gna
hippeastrum
hybrid
agglutinin
hha
repres
potenti
candid
antihiv
microbicid
show
mark
stabil
rel
low
ph
high
temperatur
prolong
time
period
directli
interact
viral
envelop
prevent
entri
hiv
target
cell
upon
prolong
exposur
hiv
cell
cultur
hha
gna
viru
acquir
resist
mutat
glycoprotein
predominantli
locat
nglycosyl
asparagin
site
avenu
explor
combin
differ
microbicid
nnrti
thiocarboxanilid
cellulos
acet
cap
viral
entri
inhibitor
exhibit
synergist
complementari
effect
infect
addit
shortag
sulfat
sulfon
polym
start
suramin
first
polysulfon
ever
shown
activ
hiv
could
consid
topic
antihiv
microbicid
compound
regist
antivir
drug
least
half
use
treat
hiv
infect
even
greater
number
compound
clinic
preclin
develop
mani
target
hiv
virus
taken
togeth
impli
hiv
sinc
advent
remain
main
target
antivir
drug
develop
antivir
agent
guid
antihiv
agent
exampl
divid
roughli
five
categori
nucleosid
analog
nucleotid
analog
acycl
nucleosid
phosphon
nonnucleosid
analog
proteas
inhibitor
viruscel
fusion
inhibitor
molecular
target
viral
dna
polymeras
whether
dnadepend
case
herpesvirus
rnadepend
case
hiv
hbv
rnadepend
dna
polymeras
revers
transcriptas
associ
hiv
rnadepend
rna
polymeras
rna
replicas
associ
hcv
proteas
associ
hiv
hcv
fusion
process
hiv
potenti
virus
sar
coronaviru
rsv
antivir
agent
may
also
exert
antivir
effect
interact
cellular
target
imp
dehydrogenas
ribavirin
sah
hydrolas
latter
enzym
essenti
viral
rna
synthesi
suppli
gtp
viral
mrna
matur
cap
respect
final
interferon
gener
provid
pegyl
form
may
advoc
therapi
viral
infect
actual
hbv
hcv
prospect
coxsacki
b
sar
yet
suffici
curb
therapeut
measur
titular
prof
p
de
somer
chair
microbiolog
teach
cours
cell
biolog
biochemistri
microbiolog
k
u
leuven
kortrijk
medic
school
professor
de
clercq
coinventor
gilead
nucleotid
analog
cidofovir
adefovir
tenofovir
receiv
hoechst
marion
roussel
call
aventi
award
maisin
prize
biomed
scienc
nation
scienc
foundat
belgium
r
descart
prize
european
union
commiss
b
pascal
award
european
academi
scienc
pioneer
effort
field
antivir
research
scientif
interest
antivir
chemotherapi
field
particular
develop
new
antivir
agent
variou
viral
infect
includ
hsv
vzv
cmv
hiv
hbv
hpv
hcv
comprehens
medicin
chemistri
ii
part
public
may
reproduc
store
retriev
system
transmit
form
mean
electron
electrostat
magnet
tape
mechan
photocopi
record
otherwis
without
permiss
write
publish
isbn
set
isbn
volum
pp
virus
viral
diseas
